Irinotecan Hydrochloride Patent Expiration
Irinotecan Hydrochloride is used for treating metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan. It was first introduced by Pfizer Inc
Irinotecan Hydrochloride Patents
Given below is the list of patents protecting Irinotecan Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Onivyde | US10456360 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US10993914 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US12059497 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US11344552 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | Aug 19, 2036 | Ipsen |
| Onivyde | US10980795 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US11369597 | Methods for treating pancreatic cancer using combination therapies | Jun 12, 2033 | Ipsen |
| Onivyde | US12364691 | Methods For Treating Pancreatic Cancer Using Combination Therapies | Jun 12, 2033 | Ipsen |
| Onivyde | US9339497 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9364473 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9452162 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9492442 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9717724 | Methods for treating pancreatic cancer using combination therapies | Jun 12, 2033 | Ipsen |
| Onivyde | US8147867 | Liposomes useful for drug delivery | Aug 29, 2028 | Ipsen |
| Onivyde | US8329213 | Liposomes useful for drug delivery | Jan 06, 2027 | Ipsen |
| Onivyde | US10722508 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US8703181 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US8992970 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US9724303 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US9730891 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US9782349 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Camptosar |
US6794370 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Nov 01, 2020
(Expired) | Pfizer Inc |
| Camptosar |
US6403569 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Oct 28, 2020
(Expired) | Pfizer Inc |
| Camptosar | US6794370 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
May 01, 2020
(Expired) | Pfizer Inc |
| Camptosar | US6403569 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Apr 28, 2020
(Expired) | Pfizer Inc |
Irinotecan Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Irinotecan Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
